---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089437"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:51:18.187307+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Liquidia Q2 net loss widens to $23.5M; YUTREPIA patent litigation advances, L606 license acquired

## Summary
- Net loss $23.5M ($0.36/sh) vs $9.4M ($0.15/sh) in Q2 2022; revenue $4.8M, up from $3.9M.
- CAFC affirmed '066 patent invalid/non-infringed; one patent ('793) on appeal to CAFC, briefing Q4 2023.
- Filed amendment to add PH-ILD to YUTREPIA label; final approval gated by Tyvaso exclusivity ending March 31, 2024.
- Licensed L606 from Pharmosa for $10M upfront; Phase 3 PH-ILD study planned in 2024 after FDA meeting.
- Cash $88.2M as of June 30, 2023, vs $93.3M at Dec 31, 2022.

## SEC filing metadata
- accession: 0001104659-23-089437
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/0001104659-23-089437-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/tm2323188d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089437
- JSON: https://secwatch.observer/filing/0001104659-23-089437.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089437.txt

## Key facts
- Earnings Releases
  Liquidia Corp reported second quarter ended June 30, 2023 results: revenue $4.8 million, net income $23.5 million, EPS $0.36 per basic and diluted share.
  - Period: second quarter ended June 30, 2023
  - Revenue: $4.8 million
  - Net income: $23.5 million
  - EPS: $0.36 per basic and diluted share
  - Result: reported results
  source text: of PH-LD patients with L606. Second Quarter 2023 Financial Results Cash totaled $88.2 million as of June 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $4.8 million for the three months ended June 30, 2023, compared to $3.9 million for the three months ended June 30, 2022. Revenue related primarily to the promotion agreement between Liquidia
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819576/000110465923089437/0001104659-23-089437-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.